Asthma and chronic obstructive pulmonary disease (COPD) are diseases with different physiological and anatomical features. However, a significant number of patients suffering from these diseases exhibit symptoms and signs which are associated with both conditions. Markers of the elevated oxidant burden have been detected in both of these disorders. This degree of overlap between asthma and COPD has proved to be especially important in smoking asthmatics, patients who have often been excluded from asthma trials and investigations. Oxidant markers are under intensive investigation as ways of assuring the early detection and monitoring of asthma and COPD, for the differentiation of the disease from the condition of "healthy smokers", and also for the evaluation of the COPD phenotypes and their progression. This review will critically review potential markers that reflect oxidative stress in the airways of patients with asthma and COPD in exhaled air, exhaled breath condensate (EBC) and induced sputum. In addition, markers in bronchoalveolar lavage (BAL) will also be briefly surveyed, even though the technique, ie, fibreoptic bronchoscopy is an invasive technique used in the investigation of lung inflammation and the evaluation of the oxidant burden. In this review, we will also discuss the pros and cons of various noninvasive biological samples for assessing the oxidant burden in the airways, and then speculate on the possibilities of using the existing and new oxidant markers, their potential combinations, and make suggestions for future investigations.

Clinical and inflammatory features of asthma and COPD
=====================================================

According to the Global Initiative for Asthma Guidelines ([@b64-copd-3-585]) asthma is defined as a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation evokes an associated increase in airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible, either spontaneously or with treatment. In the Global Initiative for Chronic Obstructive Lung Disease Guidelines ([@b67-copd-3-585]; [@b174-copd-3-585]), COPD is defined as a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. COPD is also associated with emphysematous parenchymal destruction, variable loss of lung elastic recoil, and abnormalities in gas diffusion. The physiological findings in individual patients with either clinical asthma or COPD, when isolated from the context of their environmental and clinical histories, may not allow the physician to distinguish between the conditions ([@b26-copd-3-585]; [@b56-copd-3-585]). This inability to clearly differentiate these conditions can lead to frustration in both the clinic and research settings.

There are a large number of studies and reviews on the inflammatory profile in asthma and COPD ([@b125-copd-3-585]; [@b212-copd-3-585]; [@b102-copd-3-585]; [@b36-copd-3-585]; [@b207-copd-3-585]; [@b66-copd-3-585]; [@b97-copd-3-585]; [@b189-copd-3-585]; [@b152-copd-3-585]; [@b134-copd-3-585]; [@b205-copd-3-585]). Airway inflammation is present in all forms of asthma, even in mild ([@b19-copd-3-585]) and asymptomatic cases ([@b27-copd-3-585]; [@b143-copd-3-585]) and it can be detected in both central and peripheral airways ([@b77-copd-3-585]) in asthma. There is a strong association between fractional exhaled nitric oxide (FeNO) and skin prick test scores, total immunoglobulin E (IgE) ([@b85-copd-3-585]) and blood eosinophilia ([@b195-copd-3-585]). In contrast, COPD is a disease characterized by airway inflammation with neutrophil predominance ([@b25-copd-3-585]), and periods of acute exacerbations ([@b60-copd-3-585]) with further increased airway inflammation and worsening of lung function ([@b68-copd-3-585]). Cigarette smoking is the major risk factor for development of COPD, and smoking cessation is at present the only effective way to slow down the disease progression ([@b44-copd-3-585]; [@b192-copd-3-585]). COPD exacerbations are often triggered by viral or bacterial infections consisting not only of increased numbers of neutrophils, but also of eosinophils and activated macrophages in the airways ([@b180-copd-3-585]; [@b190-copd-3-585]). Neutrophil accumulation on the other hand is one typical feature that is seen in asthma exacerbation ([@b58-copd-3-585]; [@b118-copd-3-585]). There is overlap not only in the inflammatory profile but also in the oxidant markers, especially in acute asthma and COPD exacerbations. The present review focuses on oxidant markers, but the numbers of certain inflammatory cells and the levels of cytokines have also been found to be significantly correlated with oxidant markers in the airways of patients with asthma and COPD.

The differential diagnosis of asthma and COPD is especially difficult in smoking individuals. Cigarette smoke activates macrophages and polymorphonuclear leukocytes to produce more reactive oxygen species (ROS) and this, in turn, leads to the recruitment of leukocytes into the airways ([@b155-copd-3-585]; [@b86-copd-3-585]). Since symptoms and lung function tests are indirect methods to assess the disease severity both in asthma and COPD, they may not reveal the extent of the underlying airway pathology. Smoking alone has multiple effects on the airways and there is a need to clearly differentiate the effects of smoking from the disease and its progression, a topic that has not been systematically evaluated.

Biomarker requirements in asthma and COPD differentiation
=========================================================

Oxidative stress has been claimed to be involved in the development of both asthma and COPD ([@b110-copd-3-585]; [@b143-copd-3-585]; [@b120-copd-3-585]; [@b177-copd-3-585]). There is more than one phenotype in COPD and asthma and these phenotype subtypes have not been separately evaluated with respect to the profiles of the oxidative stress burden are influenced in the different phenotypes. Currently, there is plenty of research being conducted to develop noninvasive tools for disease detection and follow-up, eg, easy-to-use devices and sensitive and specific technologies. Only practical and readily reproducible, completely noninvasive techniques offer these possibilities. The biomarkers themselves must possess certain characteristics if they are to be of any use. In addition to sensitivity and specificity, a biomarker needs to be stable, with minimal diurnal or day-to-day variability, and it should be easy to access and analyse, and still be cost-effective. Furthermore, the biomarkers should be useful for early diagnostics, differential diagnosis, response to therapy, and for the evaluation of disease progression. It is unlikely that any single biomarker can ever possess all these characteristics. Instead, panels or various combinations of biomarkers are needed. These panels could consist of different components if they are used for either the differential diagnosis or for the assessment of disease severity and its progression.

Oxidative stress in the airways in asthma and COPD
==================================================

ROS and reactive nitrogen species (RNS) are produced endogenously by several cell types including activated inflammatory and structural cells, the most potent generators of these species being eosinophils and neutrophils, ie, cells that are abundant both in asthma and COPD ([@b121-copd-3-585]). The burden of ROS/RNS is further increased by exogenous factors, mostly by environmental agents and cigarette smoke. One puff of cigarette smoke contains billions of free radicals ([@b38-copd-3-585]). These ROS, present both in asthma and smoking-related airway diseases, have multiple effects including activation of proteases, mucus secretion, airway smooth muscle contraction, airway hyperresponsiveness, and transcription of many inflammatory genes ([@b101-copd-3-585]; [@b181-copd-3-585]; [@b163-copd-3-585]; [@b217-copd-3-585]).

Oxidants present in cigarette smoke stimulate alveolar macrophages to further produce ROS, such as superoxide radical (O~2~^•−^), hydroxyl radical (^•^OH), and hydrogen peroxide (H~2~O~2~), leading to release of a number of mediators, some of which attract neutrophils and other inflammatory cells into the lungs of COPD patients ([@b67-copd-3-585]). Activated inflammatory cells generate more ROS via the NADPH oxidase system. Similarly, increased levels of xanthine oxidase, found in cell free bronchoalveolar lavage (BAL) fluid and plasma from COPD patients, can elevate O~2~^•−^ and lipid peroxide levels ([@b67-copd-3-585]). Thus, oxidants may be triggering factors for the inflammation seen in COPD. Asthma on the other hand, may be triggered by viral infections, air pollutants such as ozone and cigarette smoke, and other cellular mediators ([@b53-copd-3-585]). These agents cause influx and activation of inflammatory cells (macrophages, neutrophils, eosinophils, lymphocytes, and mast cells) which subsequently evoke the generation of inflammatory mediators. All of these converge to produce ROS which in turn leads to an increased inflammatory response, producing asthma-like symptoms. Oxidative stress is associated with activation of cytokines/growth factors but in these same conditions activated inflammatory cells produce large amounts of ROS into the airways. Thereby it can be postulated that symptoms are not only linked to the airway inflammation but also to the oxidant burden in the airways both in asthma and COPD. ROS have been shown to be associated with the pathogenesis of asthma by evoking bronchial hyperreactivity as well as directly stimulating histamine release from mast cells and mucus secretion from airway epithelial cells ([@b53-copd-3-585]). Thus, while oxidative stress due to smoking is a direct causative factor for COPD leading to a further elevation of oxidative stress, it is usually a secondary effect in asthma subsequent to a prior antigenic/allergic challenge of immune cells in the lungs.

Once oxidative stress reaches a critical level, it is difficult to demarcate between the two diseases asthma and COPD. However, site of affliction, the cells involved and the pattern of response by the lungs can help in differentiating these two diseases. In COPD, the major site of attack is the alveolar space. Inflammatory cells themselves become compartmentalized, for example, neutrophils are mainly located in the lumen of the airways and macrophages accumulate in the interstitium in COPD. COPD has been strongly associated with an accumulation of inflammatory mucous exudates in the lumen of the small airways ([@b190-copd-3-585]). In COPD, oxidant stress occurs in small airways, lung parenchyma, and the alveolar regions. In asthma, the larger airways are the major site of action, with the characteristic signs being reversible airflow obstruction, airway hyperresponsiveness/hyperreactivity, and chronic inflammation attributable to an influx of eosinophils and activation of inflammatory cells such as macrophages, neutrophils, lymphocytes, and mast cells. Airway smooth muscle contraction, increased airway reactivity and secretions, increased vascular permeability and increased generation of chemoattractants are the major features of an asthmatic response ([@b77-copd-3-585]). Hence, compartmentation of different inflammatory cells in the lungs may help clarify the type of oxidative stress response in asthma and COPD.

Many oxidants (such as O~2~^•−^ and ^•^OH) are unstable and have very short half lives, and are therefore difficult to measure. Hydrogen peroxide (H~2~O~2~) is formed from superoxide (mainly by inflammatory cells including both eosinophils and neutrophils) and is directly involved in many reactions. NADPH oxidase is one of the key superoxide generating enzymes that is expressed both in phagocytic and nonphagocytic cells ([@b99-copd-3-585]). NADPH oxidases (NOXs) and dual oxidases (DUOXs) may function as potent ROS generators in inflammatory conditions of human airways, but little is known about their role in asthma or COPD. Myeloperoxidase (MPO) is abundantly present in neutrophils and catalyses the reaction of H~2~O~2~ with chloride forming hypochlorous acid (HOCl). Eosinophil peroxidase (EPO) catalyses the reaction of H~2~O~2~ with bromide within eosinophils forming hypobromous acid (HOBr), which is released during the respiratory burst ([@b219-copd-3-585]; [@b209-copd-3-585]; [@b3-copd-3-585]). Endogenous NO is derived from L-arginine by at least three different isoforms of NOS ([@b150-copd-3-585]). Two of these are expressed constitutively (NOS1, NOS3) while the inducible form of NOS (iNOS, NOS2) can be activated by inflammatory cytokines. Inducible NOS generates the majority of the NO encountered in inflammatory states since the enzyme is induced by cytokines and is expressed in inflammatory cells (like neutrophils) as well as in nonphagocytic cells (like alveolar/bronchial epithelial and endothelial cells) ([@b17-copd-3-585]). Once ROS are generated, they rapidly attack membrane lipids leading to the generation of lipid peroxidation products such as isoprostanoids, malondialdehyde, and 4-hydroxy-2-nonenal (4-HNE). These markers have been widely used in the assessment of oxidative stress in the lung ([@b110-copd-3-585]; [@b163-copd-3-585]), but a major limitation with most of these end products is their poor specificity and reproducibility in different diseases that are related to oxidative stress. Each of these markers will be discussed below in the context of their use in asthma and COPD diagnosis and differentiation.

The antioxidant machinery of the lung is complex, containing a variety of low molecular weight antioxidants, metal binding proteins, mucus glycoproteins, and several specific antioxidant enzymes ([@b123-copd-3-585]; [@b122-copd-3-585]; [@b120-copd-3-585], [@b121-copd-3-585]). It is apparent that in oxidant-mediated airway diseases, ROS gradually overwhelm host antioxidant defenses, leading to the ultimate oxidant-mediated cell and tissue damage ([@b121-copd-3-585]). Total antioxidant capacity of plasma is decreased in smokers and patients with asthma and COPD ([@b182-copd-3-585]). It is interesting to note that the decrease in antioxidant capacity in smokers occurs transiently during smoking and resolves rapidly after smoking cessation. The depletion of total anti-oxidant capacity in smokers is associated with decreased levels of plasma antioxidants eg, ascorbic acid, vitamin E, β-carotene, and selenium ([@b182-copd-3-585]). The depletion of antioxidants may thus be a reflection of ongoing oxidative stress due to underlying inflammation in these diseases. The thiol antioxidant glutathione (GSH) and its key biosynthesizing enzyme, glutamate cysteine ligase (GCL), are decreased in the airways, and in macrophages of smokers compared to nonsmokers ([@b79-copd-3-585]). However, very little is known about antioxidant enzymes/antioxidant biomarkers in asthma and COPD or their association with disease severity or progression. It is likely that there are no specific changes in the antioxidant systems during the early phases of airway diseases, instead their changes may reflect disease severity.

Noninvasive techniques to detect airway oxidative stress: Pros and cons
=======================================================================

Exhaled air
-----------

Even though several methods have been developed to measure oxidant related damage/burden in cells, tissues, and body fluids, there has been great interest in the analysis of exhaled air since this is a totally noninvasive technique. Standardized measurements of fractional exhaled nitric oxide (FeNO) provide a noninvasive and reproducible means for monitoring asthma ([@b106-copd-3-585]; [@b8-copd-3-585]; [@b107-copd-3-585]). A wide range of commercially available analyzers exist, which decreases the cost of individual measurements. Persistent generation of oxygen radicals in the body leads to the formation of other compounds, which can also be measured from the exhaled air; these include carbon monoxide (CO) which is formed by enzymatic degradation of heme aic degradation of heme aic degradation of heme aic degradation of heme aic degradation of heme aic degradation of heme and nonheme-related release ([@b110-copd-3-585]) and hydrocarbons such as volatile organic compounds (VOC), which are nonspecific markers of lipid peroxidation ([@b126-copd-3-585]). The activation of inflammatory cells, including macrophages, eosinophils, and neutrophils, results in increased production of O~2~^•−^ and the subsequent formation of H~2~O~2~. H~2~O~2~ has been proposed to be a potential marker of oxidative stress in the lungs and this mediator has been evaluated in many investigations ([@b107-copd-3-585]). In summary, exhaled air is one of the most promising ways for the assessment of oxidative stress; it has many advantages and the technology is now being developed so that there are portable devices at a relatively low cost. There exists, in addition, a good consensus on the significance of some oxidant markers (such as FeNO) that are detectable from the exhaled air.

Exhaled breath condensate
-------------------------

Exhaled breath condensate (EBC) is condensed from water but also contains droplets that carry solute from the lower respiratory tract. The collection of EBC by cooling exhaled air has several advantages compared to many other methods of sampling the airspaces. It is simple to conduct, noninvasive, and easily repeatable ([@b110-copd-3-585]). It does not cause airway inflammation, nor does it have any significant influence on airway function ([@b14-copd-3-585]), making repeated sampling possible ([@b110-copd-3-585]; [@b109-copd-3-585]). EBC collection is relatively inexpensive and does not include any appreciable discomfort or risk to the subject. Moreover, EBC collection is also suitable for children, because it is effort-independent. It can even be applied in mechanically ventilated patients. The collection of EBC has been described in detail ([@b178-copd-3-585]; [@b90-copd-3-585]). Many nonvolatile molecules (mediators, oxidation, and nitration products) can be measured in EBC, with 8-isoprostane being the most widely measured of the oxidant markers found in EBC ([@b110-copd-3-585]). There is accumulating evidence suggesting that the abnormalities in biomarkers present in EBC may reflect the degree of asthma and COPD severity better than can be assessed by either spirometry or symptoms ([@b145-copd-3-585]; [@b110-copd-3-585]).

EBC mirrors the composition of the extracellular lining fluid (ELF) but the major drawbacks are saliva contamination, sample dilution, and high individual variability. There exists a lack of evidence of the primary origin of the aerosol particles that carry the droplets from the lower respiratory tract ([@b210-copd-3-585]). Dilution of EBC can be corrected by measuring the level of urea and/or electrolytes derived from ELF. Other confounding factors include consumption of alcohol, diets with variable amounts of antioxidants, smoking, subclinical lung diseases which have not been clinically manifested, and differences in the collection of the samples and their storage. Significant salivary contamination can be excluded by measuring the amylase concentrations in samples ([@b110-copd-3-585]), but uncertainty still exists with respect to the nasal contamination. Recommendations for EBC have been formulated by the European Respiratory Society/American Thoracic Society task force, but these recommendations also emphasized the difficulties encountered in the sampling and analysis of EBC ([@b90-copd-3-585]). To date the majority of the analyses conducted in EBC have involved spectrophotometry and enzyme immunoassays, as well as sophisticated analytical techniques such as gas chromatography/mass spectrometry (GC/MS) or high-performance liquid chromatography (HPLC). Spin trapping is one of the most direct methods available for the assessment of highly reactive free radicals/oxidants. These latter techniques require special expertise and as far as we are aware, they have not been used for assaying EBC in clinical settings. In summary, the collection of EBC is easy and it is therefore promising for the evaluation of oxidant markers. Major limitations in the EBC include the plethora of potential markers that cannot be reliably or easily analyzed in these highly diluted samples.

Induced sputum
--------------

Induced sputum represents a nearly noninvasive technique; the collection of induced sputum by hypertonic saline has been shown to be a safe ([@b211-copd-3-585]; [@b215-copd-3-585]), effective, and relatively reproducible ([@b171-copd-3-585]; [@b213-copd-3-585]; [@b57-copd-3-585]; [@b197-copd-3-585]) method for investigating airway diseases in adults ([@b172-copd-3-585]; [@b214-copd-3-585]; [@b216-copd-3-585]) and children over 6 years of age ([@b206-copd-3-585]; [@b157-copd-3-585]). Induced sputum samples provide information about both inflammatory mediators and the inflammatory cells present in the airways ([@b197-copd-3-585]) and they are believed to accurately mirror conditions at the site of oxidative damage ([@b105-copd-3-585]).

However, there is some evidence that induced sputum is sampled predominantly from the large airways ([@b4-copd-3-585]) and may not reflect the peripheral airways. Sputum induction is often difficult to accomplish, involves some discomfort to the patient, induces an inflammatory response ([@b156-copd-3-585]), and may induce coughing and bronchoconstriction in patients with COPD ([@b188-copd-3-585]; [@b204-copd-3-585]) and in asthma ([@b200-copd-3-585]; [@b9-copd-3-585]), despite pretreatment with an inhaled beta2-agonist ([@b188-copd-3-585]; [@b161-copd-3-585]). The processing of the sputum sample needs to be immediate and requires expertise and this significantly limits its use in routine clinical practice. Sampling cannot be repeated within a short period of time, and the technique itself may induce an inflammatory response, which may persist for 24 h ([@b156-copd-3-585]; [@b87-copd-3-585]). Contamination of sputum samples by saliva may lead to reduced mediator concentrations, although differential cell counts remain relatively unchanged ([@b196-copd-3-585]). On the other hand, several markers are relatively similar in the induced sputum and BAL and the technique of collecting induced sputum is much less invasive than fibreoptic bronchoscopy ([@b59-copd-3-585]). Overall, induced sputum is a standardized method and recommendations for sputum induction have been formulated by a European Respiratory Society/American Thoracic Society task force ([@b50-copd-3-585]). Induced sputum and its processing do require expertise that may be available in specialized centers though its use in a primary care setting would be demanding.

Bronchoalveolar lavage (BAL)
----------------------------

Bronchoalveolar lavage has the advantage of sampling the distal airways and alveoli in the lung periphery ([@b103-copd-3-585]). However, BAL is more invasive than the above-mentioned procedures and has also several other limitations. The invasiveness of BAL limits its clinical application in assessing airway inflammation in asthma and COPD. Generally, BAL has been performed safely on patients with stable COPD ([@b83-copd-3-585]). BAL is, however, risky to patients with moderate/severe lung disease, acute exacerbations of airway disease and also is unsuitable for children. It is also associated with sedation, impaired gas exchange and a risk of infections. Even though the BAL technique has also been standardized ([@b82-copd-3-585]), BAL fluid of COPD patients is often inadequate and not representative of the situation in the bronchioles due to airway collapse and reduced fluid recovery ([@b18-copd-3-585]). Saline instillation into the lungs can lead to artefacts, ie, the dilution of the lavage may contribute to the variability of measurements. BAL cannot be recommended for the diagnosis or follow-up of the patients with asthma or COPD.

Exhaled markers of oxidant burden in asthma and COPD
====================================================

The markers of oxidant burden that have been generally measured from the human lung are shown in [Figure 1](#f1-copd-3-585){ref-type="fig"}.

Exhaled nitric oxide metabolites
--------------------------------

Elevated FeNO levels have been widely documented in adults ([@b116-copd-3-585]; [@b169-copd-3-585]) and children ([@b136-copd-3-585]; [@b29-copd-3-585]; [@b151-copd-3-585]) with asthma, even in mild and asymptomatic conditions ([@b6-copd-3-585]; [@b110-copd-3-585]). FeNO levels correlate with eosinophilic airway inflammation and predict a decline in asthma control when repeated as longitudinal measurements ([@b111-copd-3-585]; [@b133-copd-3-585]; [@b199-copd-3-585]). The changes in serial FeNO have a higher predictive value than single measurements ([@b96-copd-3-585]; [@b132-copd-3-585]; [@b111-copd-3-585]). In addition, the level of FeNO is related to several markers of asthma control, such as asthma symptoms, dyspnea score, daily use of rescue medication, and reversibility of airflow obstruction ([@b198-copd-3-585]). Elevated FeNO levels can be detected before one can determine any significant deterioration in airway hyperresponsiveness, elevation of sputum eosinophil levels or changes in lung function parameters ([@b117-copd-3-585]; [@b96-copd-3-585]). The main site of origin of the increased levels of FeNO in asthma is the lower airways ([@b112-copd-3-585]). The measurement is highly reproducible both in healthy and asthmatic adults and children ([@b114-copd-3-585]). Measurements of exhaled NO at different flows show that the increase in peripheral NO is often related to disease severity ([@b28-copd-3-585]). Overall FeNO is one of the most widely used biomarkers in the diagnosis of asthma especially when the diagnosis is uncertain; recent results clearly highlight its benefits also in asthma management.

Exhaled NO is, however, somewhat nonspecific, for example the levels are increased in viral infections ([@b110-copd-3-585]). On the other hand, FeNO levels are generally decreased in smokers ([@b138-copd-3-585]; [@b187-copd-3-585]). There is also some disagreement on whether changes in serial FeNO are significant evidence of loss of asthma control or simply due to errors in measurements or the natural variability of airway inflammation over time ([@b107-copd-3-585]). This suggests that FeNO may not always be related to asthma severity or airway inflammation ([@b108-copd-3-585]). Development of less expensive FeNO analyzers would be beneficial, since for now FeNO analyzers are available mostly in central/university hospitals. Despite these problems, FeNO measurements have remained as one of the most important parameters in evaluating, treating, and monitoring patients with asthma and airway disease with eosinophilic inflammation.

In contrast to asthma, the FeNO levels in stable COPD do not differ significantly from controls ([@b110-copd-3-585]; [@b187-copd-3-585]). FeNO levels increase during COPD exacerbation ([@b138-copd-3-585]), most likely due to increased oxidative stress especially in cases with coexistent asthma and/or the presence of airway eosinophils ([@b162-copd-3-585]). The elevated levels of FeNO in unstable COPD compared both with stable smokers or ex-smokers with COPD are attributable to the presence of eosinophils ([@b138-copd-3-585]). On the other hand, cigarette smoke decreases FeNO levels ([@b115-copd-3-585]; [@b186-copd-3-585]) by down-regulating eNOS ([@b201-copd-3-585]) and consuming NO, making FeNO an unreliable marker for the diagnosis of asthma in smokers. FeNO has a minor role in evaluating COPD, but it may have importance in the differentiation of asthma, eosinophilic bronchitis, and COPD.

The reaction of NO and O~2~^•−^ in the airways leads to the formation of peroxynitrite (ONOO) which reacts with tyrosine residues of proteins to form a stable product, nitrotyrosine. Nitrotyrosine can be detected in EBC, its levels are increased in asthma and decreased by corticosteroid treatment ([@b78-copd-3-585]; [@b15-copd-3-585]; [@b24-copd-3-585]). However, even though both HPLC and GC/MS measurements are sensitive and detect similar nitrotyrosine levels in the EBC, they do not differentiate healthy controls from asthmatics, and therefore nitrotyrosine does not seem to be a selective marker for oxidative stress in asthma ([@b34-copd-3-585]).

Nitric oxide can be trapped by thiol-containing biomolecules (such as GSH) to form S-nitrosothiols. The levels of these compounds are elevated in the EBC of smokers and in patients with asthma ([@b41-copd-3-585]) and the levels decline with corticosteroid treatment in asthma ([@b113-copd-3-585]). Overall, the increase of the S-nitrosothiols in EBC is transitory, and probably not sensitive enough to help in the diagnostic assessment of airway diseases. Moreover, the levels of NO(x) in EBC appear to be too variable to be beneficial in clinical investigations ([@b61-copd-3-585]).

Volatile organic compounds
--------------------------

There are many volatile hydrocarbons, but only a few of them have been analyzed from exhaled air, with the most widely investigated being ethane. Elevated exhaled ethane levels have been detected in patients with mild steroid-naïve asthma compared with steroid-treated patients and normal subjects ([@b164-copd-3-585]). COPD patients display elevated exhaled ethane levels that correlate with the degree of airway obstruction ([@b165-copd-3-585]). Exhaled ethane, however, is increased by physical ([@b131-copd-3-585]) and mental stress and smoking ([@b74-copd-3-585]), probably due to the high concentrations of hydrocarbons and direct oxidative damage. Cigarette smoke itself contains ethane, and a transient elevation of exhaled ethane has also been detected in healthy smokers ([@b74-copd-3-585]). Another hydrocarbon of clinical interest is n-pentane and there are some correlations between breath pentane and serum biomarkers in smokers. Ethane is easier and faster to measure by GC/MS than the other hydrocarbons, but nonetheless these assays are difficult to conduct as the analyses require expertise, their measurement is expensive, and the biomarker itself is not specific for any particular airway disease. Moreover primary health care centers may not have access to a gas chromatograph or the necessary skills inherent in this technique. In brief, the measurement of ethane is demanding and difficult to transfer to clinical practice ([@b130-copd-3-585]; [@b18-copd-3-585]). Moreover, aldehydes can be detected both in EBC and induced sputum but their relative concentrations are different and do not correlate with each other ([@b42-copd-3-585]). There are a number of other VOCs in addition to ethane; whether their combination, ie, VOC "profiles" can be developed to be assayed by modern small gas chromatographic techniques would be an interesting area for future research. Recently, one technique, so called the electronic nose, in which expiratory vital capacity is collected and then smellprints are analyzed by linear discriminant analysis, has been found to be a promising method in differentiating exhaled breath of patients with asthma from controls even though it appears to be less accurate in distinguishing the severity of asthma ([@b51-copd-3-585]).

Carbon monoxide
---------------

Carbon monoxide (CO) is derived from the degradation of heme by hemeoxygenase or nonheme-related release from xenobiotics and bacteria. Approximately 85% of CO is exhaled ([@b110-copd-3-585]; [@b18-copd-3-585]). Many pathological conditions in addition to airway inflammation, can contribute to CO formation. One major limitation of exhaled CO in assessing oxidative stress in asthma or COPD is the marked effects of smoking on CO concentrations. The levels of exhaled CO are elevated in stable asthma and become reduced towards the normal values by administration of inhaled corticosteroids ([@b220-copd-3-585]; [@b89-copd-3-585]; [@b18-copd-3-585]). The effects of smoking make the assessment of exhaled CO in COPD difficult. Exhaled CO can be measured by electrochemical sensors, laser spectrophotometry, and by an infrared CO analysis as well as by gas chromatography, methods that are widely available in clinical laboratories. The analysis of CO is straightforward but the levels of CO are too variable to be significant in the clinical assessment of asthma and COPD, their diagnosis, or follow-up.

Hydrogen peroxide
-----------------

Exhaled H~2~O~2~ has been detected in steroid-naïve asthmatics ([@b109-copd-3-585]), patients with stable COPD and during COPD exacerbation ([@b49-copd-3-585]; [@b107-copd-3-585]) being associated with the disease severity ([@b128-copd-3-585]). Macrophages from healthy smokers release more H~2~O~2~ than the cells from nonsmokers ([@b20-copd-3-585]; [@b158-copd-3-585]; [@b71-copd-3-585]). Exhaled H~2~O~2~ concentrations are higher in smoking than nonsmoking asthmatic patients or controls, though there is extensive variability ([@b88-copd-3-585]). Acute smoking leads to a further elevation in exhaled H~2~O~2~ levels in asthmatic patients indicating that smoking causes an acute additional release of ROS in the airways ([@b88-copd-3-585]). Since H~2~O~2~ evaporates readily due to its highly unstable nature and its concentration decreases after a few days of storage at −70 °C, it needs to be assayed immediately ([@b208-copd-3-585]). One study claimed that EBC can be stored for up to 40 days without any loss of H~2~O~2~ concentration ([@b208-copd-3-585]). However, the variability of the H~2~O~2~ levels in airway fluids is high, generally the levels of H~2~O~2~ are low and the methods for H~2~O~2~ analysis are insensitive ([@b210-copd-3-585]). There are different techniques, all with their own limitations for H~2~O~2~ detection and therefore meaningful comparison of the results from various laboratories is difficult ([@b210-copd-3-585]). In summary, H~2~O~2~ is released from a number of cell types, it is relatively unstable, and its analysis is not sufficiently sensitive or specific to allow the diagnosis, differential diagnosis, or monitoring of asthma or COPD.

8-isoprostane
-------------

Oxidative damage to lipids leads to the production of isoprostanes, which are prostaglandin analogues produced primarily by free radical-induced peroxidation of arachidonic acid ([@b146-copd-3-585]). 8-isoprostaglandin F~2α~ (8-isoprostane) is the best-characterized isomer, and is considered to be a reliable index reflecting the degree of oxidative stress *in vivo*. It is a stable metabolite and specific to lipid peroxidation ([@b95-copd-3-585]; [@b147-copd-3-585]; [@b43-copd-3-585]). It has been proposed to represent an important tool for reliably exploring oxidative stress in lung diseases ([@b143-copd-3-585]). Moreover, dietary fats do not have any significant effect on the 8-isoprostane concentration ([@b69-copd-3-585]). Although antioxidants scavenge ROS, it seems that they fail to reduce the rate of lipid peroxidation ([@b7-copd-3-585]; [@b75-copd-3-585]) possibly due to the fact that lipid peroxidation is the result of a complicated metabolic pathway, where only the first step is initiated by free radicals ([@b146-copd-3-585]). Nevertheless several studies have indicated that 8-isoprostane may be an important mediator of oxidative stress and pulmonary oxygen toxicity ([@b95-copd-3-585]) and form part of a common pathway leading to airflow obstruction ([@b163-copd-3-585]).

Most studies have used commercial EIA (enzyme immunoassay) kits to detect 8-isoprostane in EBC, this technique has a good correlation with GC/MS ([@b145-copd-3-585], [@b144-copd-3-585]; [@b10-copd-3-585]; [@b128-copd-3-585]; [@b22-copd-3-585]; [@b12-copd-3-585]; [@b210-copd-3-585]; [@b19-copd-3-585]; [@b197-copd-3-585]), though there are also dissenting voices ([@b210-copd-3-585]; [@b176-copd-3-585]; [@b23-copd-3-585]; [@b197-copd-3-585]). Elevated EBC 8-isoprostane concentrations have been reported in children ([@b12-copd-3-585], [@b13-copd-3-585]; [@b142-copd-3-585]; [@b194-copd-3-585]) and adults with asthma ([@b145-copd-3-585]; [@b10-copd-3-585]; [@b19-copd-3-585]) and COPD ([@b144-copd-3-585]; [@b128-copd-3-585]; [@b22-copd-3-585]; [@b127-copd-3-585]). The concentrations increase with asthma severity ([@b145-copd-3-585]; [@b110-copd-3-585]) and decline following resolution of acute asthma exacerbations, though they still remain higher than in healthy individuals ([@b12-copd-3-585]). EBC 8-isoprostane concentrations decline after allergen avoidance in children with allergic asthma ([@b23-copd-3-585]), but are relatively resistant to inhaled corticosteroid therapy ([@b145-copd-3-585]; [@b12-copd-3-585], [@b13-copd-3-585]; [@b142-copd-3-585]; [@b194-copd-3-585]). The levels do not correlate with FeNO ([@b12-copd-3-585]) or lung function parameters in children with asthma ([@b13-copd-3-585]; [@b194-copd-3-585]). The levels of 8-isoprostane are increased in EBC of COPD irrespective of smoking status and lung function impairment ([@b144-copd-3-585]), increasing further during exacerbations of COPD, and declining after antibiotic treatment ([@b22-copd-3-585]). Smoking seems to evoke an acute 50% increase in EBC 8-isoprostane levels within 15 minutes ([@b144-copd-3-585]). The 8-isoprostane concentrations in EBC do not correlate with age, sex, or history of smoking in pack-years ([@b144-copd-3-585]). No associations have been found between the levels of 8-isoprostane and dyspnea score, neutrophil count, or lung function parameters ([@b144-copd-3-585]).

There are still major limitations in the detection of 8-isoprostane in the EBC, the concentrations are variable and often remain below the detection limit of the analysis ([@b210-copd-3-585]). These limitations may be partly related to the extensive dilution that occurs from water vapour during condensation and the low concentrations to be assayed that are near the detection limits of the EIA measurements ([@b54-copd-3-585]). Other confounding factors include smoking, diurnal variation, age, alcohol consumption, caffeine and possibly also a diet rich in antioxidants. Several studies have also clearly revealed extensive variation in the levels of 8-isoprostane in nonsmokers and smokers suggesting that the commercial assay itself is variable. Based on the earlier and recent studies, it appears that EBC 8-isoprostane may not be very sensitive or specific biomarker of oxidative stress given the variability in its measurement. The actual significance of 8-isoprostane and its detection methods (eg, standardization) in the EBC still await clarification.

Markers of oxidative stress in induced sputum
=============================================

Oxidant**-**generating enzymes
------------------------------

The most important oxidant-generating enzymes that have been assessed in induced sputum specimens include iNOS, EPO, and MPO ([@b121-copd-3-585]). The main location of iNOS, which is the most efficient of the NO synthases in producing NO during inflammation, is the airway epithelium, but it has also been detected in inflammatory cells ([@b17-copd-3-585]). Although, the levels of iNOS have been found to be elevated in the induced sputum of asthmatics ([@b202-copd-3-585]), variable levels of iNOS have been reported in COPD patients ([@b92-copd-3-585]; [@b187-copd-3-585]). EPO is elevated in asthma while MPO, which is expressed in neutrophils and monocytes ([@b119-copd-3-585]), is elevated in COPD with the levels being higher in COPD than in asthma ([@b140-copd-3-585]). A rather similar elevation in the number of MPO-positive cells is seen in the induced sputum of chronic nonsymptomatic smokers and chronic symptomatic smokers with normal lung function, who are considered to be at risk of developing COPD ([@b187-copd-3-585]). Sputum MPO concentrations have been reported to be extremely variable in several investigations with large standard deviations ([@b119-copd-3-585]). However, EPO and MPO may possess potential significance in differentiating asthma from COPD. MPO leads to the formation of HOCl and EPO to HOBr. These markers still seem to offer the greatest potential in the differentiation of asthma and COPD but both of them have been evaluated in only a few investigations. In one study, the best results when determining the most optimal fixation procedure to detect MPO and EPO in cytocentrifuged cell samples (induced sputum, BAL) were obtained using a commercial reagent Ortho PermeaFix (OPF; Ortho Clinical Diagnostics, Raritan, NJ) for flow cytometry ([@b139-copd-3-585]). EPO was found to be a useful marker for the identification of eosinophils in sputum and bronchoalveolar lavage since anti-EPO antibodies reacted only with eosinophils ([@b141-copd-3-585]).

3-nitrotyrosine
---------------

The reaction of NO and O~2~^•−^ in the airways leads to the formation of peroxynitrite which reacts with tyrosine residues of proteins to form the stable product, nitrotyrosine ([@b93-copd-3-585]). Nitrotyrosine can be formed not only by iNOS activation but also by MPO ([@b46-copd-3-585]). Increased nitrotyrosine immunoreactivity has been reported in the lung biopsies of asthmatics ([@b191-copd-3-585]), in EBC from asthmatic adults ([@b78-copd-3-585]) and children ([@b15-copd-3-585]) as described above and it is associated with asthma exacerbation. Nitrotyrosine may play a major role in the pathogenesis of airway remodelling, ([@b110-copd-3-585]) and it may contribute to airway obstruction and hyperresponsiveness and epithelial damage in asthma ([@b191-copd-3-585]). Abundant iNOS and nitrotyrosine positive sputum cells have also been seen in COPD patients compared to healthy smokers with a negative correlation to FEV~1~ ([@b92-copd-3-585]). However, the sputum samples of smokers without airway obstruction and also some samples of nonsmokers display increased levels of nitrotyrosine ([@b187-copd-3-585]). It is likely that nitrotyrosine is not specific in differentiating between asthmatic and cigarette smoke-related airway disease.

8-isoprostane
-------------

Recent evidence suggests that sputum 8-isoprostane mirrors airway oxidative stress and is related to respiratory disease type pattern and activity ([@b218-copd-3-585]). The level of 8-isoprostane is higher in sputum than in EBC ([@b197-copd-3-585]). Sputum 8-isoprostane is higher in adults with stable asthma than in healthy subjects, increase further with disease severity and decrease significantly after treatment of acute asthma exacerbation, although there is a wide variability in the 8-isoprostane concentrations between and within the groups ([@b218-copd-3-585]). Moreover, a recent study could not detect any difference between sputum 8-isoprostane levels in mild asthmatics and healthy controls ([@b135-copd-3-585]). Sputum 8-isoprostane levels are elevated in COPD and cigarette smokers, but do not clearly differentiate healthy smokers from symptomatic smokers, ie, those who are at risk for developing COPD ([@b124-copd-3-585]). No longitudinal studies have been conducted with this marker, making it difficult to draw any final conclusions about its real significance. As described above, the major problems with this marker include the poor sensitivity, specificity and the fact that commercial EIA method and/or the impurities of the samples may contribute to its levels in sputum specimens.

4-hydroxy-2-nonenal
-------------------

Aldehydes generated endogenously during lipid peroxidation may be involved in many pathophysiologic events associated with oxidative stress in cells and tissues ([@b72-copd-3-585]). 4-HNE is a highly reactive and diffusible end-product of oxidative stress-induced lipid peroxidation that can attack targets far from the original site of free radical generation ([@b55-copd-3-585]). It is hypothesized that the degree of formation of 4-HNE in response to smoking may also contribute to the development of enhanced airspace inflammation in COPD ([@b183-copd-3-585]). 4-HNE can be detected in lung biopsies of COPD patients ([@b183-copd-3-585]), but recently it has also been detected in induced sputum samples of chronic smokers, irrespective of the lung function parameters or symptoms compared to nonsmokers ([@b187-copd-3-585]). These results suggest that even though 4-HNE confirms that oxidative damage has occurred, it may not provide specific insight into the pathogenesis of the airway disease, and may not be a sensitive biomarker for assessing the disease severity.

Antioxidants and antioxidant enzymes
------------------------------------

The oxidant/antioxidant equilibrium is disturbed in asthmatic and COPD patients not only due to the chronic inflammation, activation of inflammatory cells and/or oxidant producing enzymes but also due to changes in the antioxidant defense of the lung. It is believed that the major low molecular weight antioxidant of human airway secretions is GSH ([@b30-copd-3-585]) but how well its levels are maintained in the ELF is still poorly understood. In addition to free GSH, a major proportion of GSH is bound to proteins and this fraction is difficult to measure. GSH has been investigated both in airway secretions and BAL but it has been shown to be neither sensitive nor specific for asthma or COPD.

The first line of defense enzymes against superoxide radicals involves superoxide dismutases (SOD) such as MnSOD and there are suggestions that MnSOD may become inactivated in the airways of asthma patients ([@b40-copd-3-585]). Enzymes related to GSH synthesis/homeostasis such as glutathione peroxidases (GPx) play an important role in the antioxidant defense of human lung ([@b30-copd-3-585]). Extracellular glutathione peroxidase (eGPx) has not been investigated in sputum specimens but it is increased in the BALF of asthma patients ([@b39-copd-3-585]). Glutaredoxins (GRX) participate in GSH binding to proteins and thiol oxidation/reduction, reactions that regulate the active forms of many thiol containing enzymes. GRX-1 is mainly expressed by macrophages ([@b167-copd-3-585]) and the levels are decreased in the sputum macrophages of COPD patients ([@b168-copd-3-585]). Glutathione-S-transferase omega, which has many functional features in common with GRX, has been recently found to be expressed mainly in alveolar macrophages, and similar to GRX-1, its levels also decline in COPD ([@b81-copd-3-585]). Catalase is expressed both in the inflammatory cells and alveolar epithelium, and it is inactivated at least in the murine model of asthma ([@b65-copd-3-585]). Heme oxygenase 1 (HO-1) is an enzyme induced by oxidant stress (stress-response protein) and cytokines. It is expressed mainly in alveolar macrophages of human lung and macrophages of induced sputum of steroid-naïve asthmatics show prominent but only transient HO-I immunoreactivity. This is not seen in asthmatics treated with corticosteroids ([@b80-copd-3-585]). The expression of HO-1 is increased also in the sputum macrophages of COPD patients compared to healthy nonsmokers, but there is no difference between COPD patients and healthy smokers ([@b137-copd-3-585]). Cigarette smoking increases especially the RNA expression of GSH-related enzymes in the bronchial brushings of healthy individuals ([@b76-copd-3-585]), but the RNA levels of antioxidant enzymes in the bronchial epithelium have high variability in COPD depending on its severity ([@b170-copd-3-585]). Even though the above mentioned findings have not been confirmed in sputum, the results are interesting; they suggest that combined profiles of antioxidant and detoxification enzymes and their posttranslational modifications (such as oxidation, thiolation, S-nitrosylation) may be promising indicators of the severity of oxidative stress in human airways.

Matrix metalloproteinases
-------------------------

Matrix metalloproteinases (MMPs) are a large family of proteolytic enzymes (over 30 MMPs have been characterized) that degrade the components of the extracellular matrix ([@b159-copd-3-585]). These enzymes are involved in the pulmonary remodelling processes that underpin both asthma and COPD ([@b166-copd-3-585]; [@b104-copd-3-585]). Oxidative stress, mainly cigarette smoke associated oxidants, may be one of the major factors contributing to MMP activation. MMPs can be readily detected in sputum specimens. There are significant differences in the MMP profiles in COPD and asthma. In COPD, elevated levels of MMP--1, --8, and --9 compared with asthmatics, nonsmokers, and non-symptomatic cigarette smokers have been reported, and these changes may also reflect the different pathogenesis of these diseases ([@b45-copd-3-585]). In the future, MMPs may be considered as additional biomarkers in COPD and/or asthma development. These markers also hold potential in evaluating COPD phenotypes, since the emphysematous type of COPD would be predicted to exhibit a different profile of MMPs than the disease where there is airway predominance.

Oxidant markers in bronchoalveolar lavage
=========================================

The total BAL cell profile and also the cell count differ in asthma and COPD. The number of inflammatory cells, especially neutrophils, are higher in COPD patients suffering exacerbations compared with stable COPD patients or healthy controls ([@b52-copd-3-585]). BAL fluid has been widely used for the assessment of inflammatory cytokines such as interleukin-8 (IL-8) and tumor necrosis factor alpha (TNFα) in asthma and COPD ([@b1-copd-3-585]; [@b52-copd-3-585]). The most widely investigated marker of oxidant/antioxidant balance in BAL fluid is GSH, the levels of which are increased in smokers and patients with stable COPD compared to the nonsmokers, but reduced during exacerbations as compared to the levels found in stable COPD ([@b52-copd-3-585]). On the other hand, older smokers with a long-term smoking history exhibit elevated oxidized glutathione (GSSG) and protein carbonyls in their BAL fluid even in the absence of any lung disease, indicating that lung antioxidant defences have become overwhelmed the prolonged exposure to the noxious substances present in cigarette smoke ([@b149-copd-3-585]). 8-isoprostane and some other oxidant markers have been compared between EBC and BAL, but clinical disease markers of inflammation and oxidative stress in EBC and BAL do not correlate with each other ([@b94-copd-3-585]). Thus, even though some markers in BAL fluid may seem to offer promise in the assessment of inflammation, BAL is too invasive and not sensitive enough to be of use in the assessment of oxidative stress/airway inflammation in clinical practice.

Pitfalls in measuring ROS in smoking asthmatics
===============================================

One problem in assessing the importance of oxidant-related biomarkers, for example FeNO and 8-isoprostane, is that smoking *per se* has significant effects on the levels of these markers, and this phenomenon is especially important in asthma. The prevalence of active cigarette smoking among asthmatics is as common as it is in the general population, for example in Finland as many as 30% of asthmatics are smokers ([@b73-copd-3-585]). There is limited data on the airway pathology of smoking asthmatics, since these patients are frequently excluded from experimental studies. Asthma and cigarette smoking potentiate the effects of each other, leading to impaired asthma control, more severe symptoms ([@b5-copd-3-585]), increased need for rescue medication ([@b62-copd-3-585]), accelerated deterioration of lung function ([@b129-copd-3-585]) and reduced short-term therapeutic response to corticosteroids ([@b37-copd-3-585]). Smoking may also modify the typical asthmatic inflammation profile, which complicates the differential diagnosis from COPD. It also appears that there are features of both accelerated and suppressed inflammatory responses in smokers with asthma. The number of eosinophils in sputum are decreased ([@b35-copd-3-585]), perhaps due to the exogenous NO in cigarette smoke increasing apoptosis of activated eosinophils ([@b11-copd-3-585]) whereas the number of neutrophils is elevated ([@b35-copd-3-585]). Many asthmatic smokers have mixed features of typical asthmatic and smoke-related airway inflammation and pathology. Results from clinical studies suggest that smokers with asthma may be resistant to therapeutic effects of the corticosteroids ([@b35-copd-3-585]; [@b37-copd-3-585]). There is also evidence that the time of initiation of smoking may influence the asthma phenotype: atopy-associated asthma has been shown to develop before smoking initiation ([@b175-copd-3-585]). It has been claimed that the remodeling of airways might be more severe in asthmatic smokers ([@b32-copd-3-585]). Several markers of oxidative/nitrosative stress are increased even in "healthy" smokers, but we are not aware of any studies where the oxidant markers have been compared between healthy smokers and smoking asthmatics. It is apparent that the sensitivity of FeNO to detect a worsening of asthmatic inflammation in smokers is poor, since smoking on its own decreases FeNO levels significantly.

Disease progression, COPD phenotypes, and oxidative stress
==========================================================

The evaluation of oxidative stress in disease progression is especially complex in COPD. The symptoms do not closely reflect spirometric changes and the symptoms may predict exacerbation only in some individuals ([@b193-copd-3-585]). COPD exacerbations in turn are important events in terms of disease progression, morbidity, and mortality. Many patients with COPD never recover completely from the exacerbation. The lung pathology is especially complex in COPD as the disease contains many phenotypes displaying a wide variety of airway and emphysematous changes. However, all phenotypes are treated similarly, because there are no specific biomarkers for the differentiation of the disease subtypes or their progression. At present, no biomarker in clinical practice is able to differentiate small airway inflammation and fibrosis from alveolar destruction even though these changes are the main pathophysiologic events in COPD ([@b18-copd-3-585]). Special efforts should be directed towards finding reliable biomarkers that would differentiate the phenotypes of COPD in addition to identifying markers that can be used in the assessment of disease progression. Though outside the scope of this review, which concentrates on local airway biomarkers, a number of biomarkers in the circulating blood/plasma and in the skeletal muscle are under intensive investigation as ways of monitoring the progression of COPD ([@b2-copd-3-585]; [@b70-copd-3-585]; [@b91-copd-3-585]; [@b98-copd-3-585]).

Several studies have highlighted the usefulness of 8-isoprostane in the evaluation of oxidative stress in COPD and during COPD exacerbations. This agent is known to exert biological activity such as evoking the contraction of human bronchial smooth muscle *in vitro* ([@b163-copd-3-585]), and being able to elicit airway hyperresponsiveness ([@b84-copd-3-585]) and evoke airway obstruction and plasma exudation ([@b160-copd-3-585]), evidence that it may be involved in the pathophysiology and progression of COPD. Many cross-sectional studies have shown that 8-isoprostane levels correlate with lung function parameters, but these findings have not been confirmed in longitudinal investigations. As far as we are aware there are no studies to explain how elevated 8-isoprostane levels are associated with COPD phenotypes, respond to treatment in COPD, or whether 8-isoprostane can be used in the follow-up of these patients.

Several markers of oxidant burden have been suggested to associate both with the pathogenesis and disease progression of asthma ([@b16-copd-3-585]) and COPD ([@b185-copd-3-585]). Considering the complexity of oxidative stress and the inflammatory cascade and the interaction between these two processes, it is, however, unlikely that measurement of any single molecule in the EBC, sputum, or in biological fluids would be able to provide adequate information about disease progression. Potential current markers that could possibly be used for the assessment of the disease severity or progression include the combination of several markers such as EBC VOC profiles with small detectors, FeNO, sputum oxidant markers, specific MMPs, and selected antioxidant enzymes.

Antioxidant therapies and disease progression
=============================================

Since it seems likely that asthma and COPD are associated with an elevated oxidant burden, these diseases might be treated with exogenous antioxidants or related strategies. It is likely that vitamins taken orally do not reach the critically damaged areas of the lung, which has its own highly specific antioxidant systems. Several attempts have been made to improve GSH homeostasis by treatment with inhaled and oral GSH, since the level of GSH is much higher in the epithelial lining fluid than in any other organ or circulating blood, and decreased by oxidative stress. However, GSH is poorly absorbed through membranes and inhaled GSH itself has been shown to cause bronchoconstriction ([@b179-copd-3-585]). N-acetyl-L-cysteine (NAC) may improve GSH balance but this compound is known to also possess GSH-independent pro-oxidant effects at the cellular level. NAC has been tested and administered by inhalation, orally and intravenously ([@b179-copd-3-585]). Oral NAC has been shown to decrease the risk for COPD re-hospitalisations ([@b63-copd-3-585]) and to decrease H~2~O~2~ levels in the exhaled air in COPD ([@b100-copd-3-585]), but the results of the multicenter BRONCUS-trial revealed no major effects on lung function values or COPD exacerbations ([@b48-copd-3-585]; [@b47-copd-3-585]). A recent systematic review on NAC indicated that the use of NAC could significantly reduce the odds of exacerbation in patients with COPD ([@b203-copd-3-585]) and therefore could possibly have effects on disease progression. Whether the new antioxidant mimetics that are under development will have benefits in asthma or COPD will be an interesting area of future investigation.

Perspective/conclusions
=======================

The assessment of noninvasive biomarkers in asthma and COPD is an area of intensive investigation. Noninvasive specimens that reflect oxidative stress in the airways include exhaled air, EBC, and induced sputum. Induced sputum is a widely used technique and there are many advantages in using induced sputum both in asthma and COPD. One practical problem with induced sputum, however, is the fact that it is not totally noninvasive and sample processing requires expertise. Nonetheless, induced sputum is promising especially for the analysis of markers with different roles in the pathogenesis of asthma and COPD. One example is the differentiation of the subphenotypes (either airway or emphysema predominance) of COPD by combining the existent knowledge of oxidant markers in the sputum specimens and expanding the methodology to new technologies including proteomics (sputome).

Exhaled air and EBC are totally noninvasive and therefore most interesting for the clinical evaluation of airway diseases, their differential diagnosis and progression. FeNO has been the most widely used of the various markers and has been shown to have clinical significance in asthma, its differential diagnosis and monitoring ([Table 1](#t1-copd-3-585){ref-type="table"}). Further emphasis should be directed in the development of small, easy-to-handle, portable devices for the investigation of the exhaled gas profiles (such as VOCs) and their role especially in COPD. Real time analysis of volatile organic molecules by infrared laser spectroscopy enables online measurement of oxidative markers ([@b148-copd-3-585]) and these techniques offer the potential for real time monitoring of EBC also in asthma and COPD. Metabolomic analysis (quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification) ([@b154-copd-3-585]) can provide new biochemical profiles for the assessment of low molecular weight metabolites in EBC. These methods include nuclear magnetic resonance (NMR) and allow simultaneous detection of hundreds of low molecular weight species within a single fluid sample. These NMR "fingerprints" may further improve the characterization of the specific features in asthma and COPD and their differentiation ([@b31-copd-3-585]). Lipidomics has been evaluated in vitro and in the developing lung ([@b173-copd-3-585]; [@b21-copd-3-585]), but its value in asthma and COPD remains to be confirmed in the future.

Many investigations have used sophisticated techniques such as microarray or proteomics which generate enormous amounts of information that is difficult to interpret even by the investigators. It is clearly challenging to extrapolate these results from a specific cell type (for example bronchial epithelial cells obtained by bronchial brushing) or from total lung homogenate to a noninvasive specimen such as exhaled air or sputum. It is likely that proteomics offers multiple advantages compared to the gene expression studies since proteins and not genes ultimately determine cellular function ([@b184-copd-3-585]). Proteomic studies have also revealed a total of nearly 200 human proteins from the induced sputum specimens (sputome) ([@b153-copd-3-585]; [@b33-copd-3-585]) and these profiles may differ in various airway diseases and phenotypes ([@b33-copd-3-585]). Recent studies have also discovered panels/clusters of oxidant/antioxidant enzymes that may be utilized for the assessment of disease severity. Overproduction of ROS can also cause oxidative modifications of several important antioxidant/defense enzymes, which may be associated with alterations in enzyme conformation and thus they can function as markers of the degree of oxidative stress present in the airways. These changes that currently can be analyzed by 2DE electrophoresis and MS but in the future new potent nongel-based proteomic methods may represent the next generation of more specific biomarkers both for asthma and COPD. In view of the overlapping patterns of the profiles of various oxidant biomarkers in asthma and COPD, the utilization of very sophisticated techniques in their assessment is important. Since cigarette smoking is inevitably related to COPD and since smoking only partly overlaps with the pathophysiology of asthma, new tools might offer an easier and cost-effective way for early diagnosis and differentiation of asthma and COPD. The future directions in the search for potential markers of oxidant burden are summarized in [Table 2](#t2-copd-3-585){ref-type="table"} and [Figure 2](#f2-copd-3-585){ref-type="fig"}.
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![The markers of oxidative stress are derived from different cells and cell compartments in the alveolar or bronchiolar wall. Neutrophilic granulocytes express myeloperoxidase (MPO) and eosinophilic granulocytes are endowed with eosinophilic peroxidase (EPO). Inducible nitric oxide synthase (iNOS) is expressed in the inflamatory cells and bronchial epithelium. 4-hydroxy-2-nonenal (4-HNE) and 3-nitrotyrosine can be detected in a variety of cell types. Hydrogen peroxide (H~2~O~2~), nitric oxide (NO), carbon monoxide (CO), and 8-isoprostane (8-iso) represent widely investigated markers in the exhaled air/exhaled breath condensate.](copd-3-585f1){#f1-copd-3-585}

![Future strategies for the discovery of new biomarkers in asthma and COPD, their diagnosis, differential diagnosis and assessment of the COPD phenotypes. The methods include microarray and proteomics combined with novel technologies. In these studies, protein expression has multiple advantages compared to gene expression, since proteins and not genes finally determine cellular function. Methods such as metabolomics (analysis of low molecular weight molecules from exhaled breath condensate), lipodomics and sputome (proteomics from induced sputum) have been evaluated and are ready for clinical prospective studies in asthma and COPD. Microarray/proteomics obtained from lung tissue, bronchial brushings and/or bronchoalveolar lavage have been conducted in asthma and/or COPD, and their extrapolation to noninvasive samples is being investigated in many laboratories.](copd-3-585f2){#f2-copd-3-585}

###### 

The principal noninvasive methods in assessing airway inflammation and oxidative stress from patients with known or suspected obstructive pulmonary disease. The list includes some markers that already are in clinical use as well as several markers in experimental use

  Specimens                      Advantages                                                                  Disadvantages                                                                      Markers
  ------------------------------ --------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Exhaled air                    Noninvasiveness, useful for children, follow up of asthmatic inflammation   Minor significance in COPD,                                                        [FeNO]{.ul}, ethane, H~2~O~2~, CO
  Exhaled breath condensate      Noninvasiveness, useful for children                                        Problems with sample dilution, lack of standardization and specificity             H~2~O~2~, 8-isoprostane, cytokines,
  Induced sputum                 Informative; inflammatory cell profile                                      Can cause inflammation/bronchoconstiction, requirements for laboratory standards   [Inflammatory cells. EPO]{.ul}, [ECP]{.ul}, [MPO]{.ul}, iNOS, Nitrotyrosine, 8-isoprostane, 4-HNE, MMPs
  Bronchoalveolar lavage fluid   Accurate, standardized method                                               Invasiveness. Information is obtained only from the alveolar level                 [Inflammatory cells and selected cytokines]{.ul}, GSH, MMPs

**Notes:** The best potential current markers in the differential diagnosis of asthma and COPD are underlined. Among all oxidant markers FeNO is widely used in clinical practice.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide; CO, carbon monoxide; H~2~O~2~, hydrogen peroxide; iNOS, inducible nitric oxide synthase; EPO, eosinophilic peroxidase; ECP, eosinophilic cationic protein; MPO, myeloperoxidase; 4-HNE, 4-hydroxy-2-nonenal; MMPs, matrix metalloproteinases; GSH, glutathione.

###### 

Potential noninvasive oxidant biomarkers for the assessment of asthma, COPD, their differential diagnosis and phenotypes by combining the existent knowledge and future technologies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Exhaled air/exhaled breath condensate (EBC)**
  FeNO (various flow rates)Profiles/clusters of volatile compounds by using new gas chromatographic/MS technologiesMetabolomics (Assessment of low molecular weight compounds in EBC)
  **Induced sputum**
  Combinations of certain oxidant markers and footprints of oxidative damage (differential diagnosis, disease severity)Combinations of certain antioxidant enzymes (disease severity)Posttranslational modifications/inactivation of the antioxidant/detoxification enzymes in human lung (disease severity)Matrix metalloproteinases and their specific combinations (disease severity, differential diagnosis, phenotype)Sputome (proteomics from induced sputum) (differential diagnosis, disease severity, phenotype)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
